help@troutgroup.com
+1 646 378-2900
Login
Register for Event
Toggle navigation
Home
Blog
Podcasts
Contact
Form
Help
Help
Privacy Policy
Sign in with LinkedIn
GenSight KOL Event June
Overview
Register / Log In
GenSight Biologics
GenSight KOL Event June
New York, June 12, 2018
Please turn on cookies and JavaScript in your browser in order to use this page. If that is not possible, please contact Solebury Trout for registration.
Please turn on cookies and JavaScript in your browser in order to use this page. If that is not possible, please contact Solebury Trout for registration.
Register for Event / Log Back in
Additional menu options can be found in the menu bar on the left or at the top.
GenSight Biologics
[SIGHT:PA]
€40 MM MCap
Gene therapy: retinal & CNS degenerative pathologies and mitochondrial disease. Filing for MAA exp Q1 2020 in EU and Q4 2020 in US. Optogenetic program and targeted disease immediately transferable to dry AMD. Platform combines mono-genetic therapy-based approach w core technology platform and proprietary Mitochondrial Targeting Sequence. [more information]